Loading…
← CockpitCompetitor Analysis › 605116.SS Aurisco Pharmaceutical Co. Ltd. Class AOpen in the cockpit ↗

Aurisco Pharmaceutical Co. Ltd. Class A605116.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang-based active pharmaceutical ingredient and CDMO manufacturer exporting to generic-drug makers abroad.

≈ A small Chinese API/CDMO exporterMomentum neutral 41
Mkt cap
$1.00B
US dollars, full cap
Free float
16%
of shares outstanding
$/day
$4.99M
20-day average traded
Fwd P/E
13.6×
forward earnings
ROIC−WACC
+8.0 pp
WACC 5.0%
Hurdle
-21 pp
Req g minus delivered
Next earnings
155 days
22 Apr 2027
Close · CNYCN¥16.57
1D-1.4%
1W-8.8%
1M-12.1%
3M-21.7%
6M-23.0%
YTD-33.9%
1Y-29.3%
ATR %3.4%
52w lowhigh53.4% off high

What Aurisco Pharmaceutical does

Zhejiang-based active pharmaceutical ingredient and CDMO manufacturer exporting to generic-drug makers abroad.

In one line: A small Chinese API/CDMO exporter.

Products and services

  • Active pharmaceutical ingredients
  • CDMO contract manufacturing

Customers

  • Overseas generic-drug makers

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • API manufacturing and CDMO

What could go right

  • Export demand for API/CDMO capacity

What could go wrong

  • FX and export price competition

Moat: none (scale). Commodity API/CDMO producer competing mainly on cost and regulatory filings.

Headquarters: Taizhou, Zhejiang, China · Employees: 2,026

Named competitors

Aurisco Pharmaceutical at a glance

Size Aurisco Pharmaceutical (605116.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.00B, the 2161st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.57 on 18 Nov 2026.

Performance Over six months the shares fell 23.0%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 3.1% over the last twelve months (peer median +8.3%); the operating margin is 25.2% (peer median 8.9%).

Valuation It trades at 13.6× forward earnings against a peer median of 20.6× (6th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -21 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.0 points above its cost of capital (5.0% WACC).

Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 92605116.SS 78
Six months, rebased to 100: Aurisco Pharmaceutical against the median of its 20 peers (local-currency closes).

Aurisco Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.67BCN¥1.69BCN¥1.47BCN¥1.26BCN¥1.00B
Revenue growth—+15%+17%+25%—
Gross profitCN¥1.01BCN¥967MCN¥826MCN¥671MCN¥491M
EBITDAn/aCN¥658MCN¥474MCN¥358MCN¥279M
Net incomeCN¥317MCN¥449MCN¥355MCN¥289MCN¥211M
Free cash flowCN¥41.4MCN¥78.0M-CN¥204MCN¥80.2M-CN¥49.6M
Capital expenditureCN¥367MCN¥350MCN¥540MCN¥305MCN¥216M
Total debtCN¥1.03BCN¥1.03BCN¥1.04BCN¥271MCN¥145M

Quarterly statements and history in the cockpit →

Aurisco Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%6880916887104887600557000650300702AARTIPHARM688382600129SPTXPGHL30049768851345654553002737SVRA688759BSLN605116.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Aurisco Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×20×40×60×6887104887600557000650300702600129PGHL3004976885134553002737300294BSLN605116.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Aurisco Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%68871060055700065030070268838230049745654553002737BSLN605116.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Aurisco Pharmaceutical is the large dot.

Aurisco Pharmaceutical competitors and peer comparison

Head to head with its named competitors (605116.SS vs 600521.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Aurisco Pharmaceutical 605116.SS$1.00B-23%+3%25%13.6×-2.0%
Zhejiang Huahai Pharmaceutical 600521.SS$3.61B0%+10%12%20.1×6.4%

How Aurisco Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Aurisco Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure605116.SSPeer medianRank in peer set
1-month return-12.1%-5.0%4th lowest of 21
6-month return-23.0%-10.6%6th lowest of 21
Distance from 52-week high-53.4%-32.1%3rd lowest of 21
Revenue growth (TTM)+3.1%+8.3%7th lowest of 18
Operating margin25.2%8.9%2nd highest of 18
Forward P/E13.6×20.6×6th cheapest of 15
Growth the price implies (Req g, 7 yrs)-2.0%4.4%4th least demanding of 13
Growth delivered (Del g)+18.7%+5.6%3rd highest of 13
Hurdle (Req g minus delivered)-20.8 pp-3.5 ppleast demanding of 13
ROIC minus cost of capital+8.0 pp-0.2 pp3rd highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%

Questions

Who are Aurisco Pharmaceutical's main competitors?
Named competitors: Zhejiang Huahai Pharmaceutical (600521.SS). The cockpit's measured peer set (industry) also includes Shanghai Yizhong Pharmaceutical (688091.SS), Shanghai InnoStar Bio-tech (688710.SS), SAWAI (4887.T), Jiangsu Kanion Pharmaceutical (600557.SS), Renhe Pharmacy (000650.SZ), Zhejiang Tianyu Pharmaceutical (300702.SZ).
Is Aurisco Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 13.6× against a peer median of 20.6×, 6th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -21 pp: the price already allows for a slowdown.
How has Aurisco Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -23.0% against -10.6% for the median peer; over one year -29.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.